Showing results (81-90 of 444) with videos related to
Sort By:
Pageof 45
Future Oncology (London, England)|June 1, 2012
BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutationKate Young, Anna Minchom, James LarkinJournal of Immunotherapy (Hagerstown, Md. : 1997)|December 16, 2020
Checkpoint Inhibitor-associated Cutaneous Small Vessel Vasculitis: A Review of the LiteratureBernard Ho, James Larkin, Kara HeelanHealth Promotion International|December 10, 2024
Commercial influences on patient and public involvement: a renewed call for research and actionMarita Hennessy, Tom Fahey, James LarkinFuture Oncology (London, England)|October 6, 2010
Sunitinib for metastatic renal cell carcinomaDeborah Mukherji, James Larkin, Lisa PickeringProgress in Tumor Research|September 18, 2015
Immunotherapies in Early and Advanced Renal Cell CancerBenjamin Kasenda, James Larkin, Martin GoreFuture Oncology (London, England)|November 3, 2011
Ipilimumab: showing survival benefit in metastatic melanomaAnna Minchom, Kate Young, James LarkinExpert Opinion on Biological Therapy|February 3, 2025
Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challengesSowmya Cheruvu, David McMahon, James LarkinTherapeutic Advances in Urology|October 2, 2012
Experience with sunitinib in the treatment of metastatic renal cell carcinomaManuela Schmidinger, James Larkin, Alain RavaudSeminars in Cancer Biology|June 19, 2012
Current and future systemic treatments for renal cell carcinomaRosalie Fisher, Martin Gore, James LarkinExpert Review of Anticancer Therapy|April 21, 2011
Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of actionJames Larkin, Charles Swanton, Lisa PickeringPageof 45